Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Multiple myeloma outlook: Keeping the cobra in the basket

This article was originally published in Scrip

Executive Summary

Is multiple myeloma treatment at a tipping point? With new treatment approaches based on monoclonal antibodies and immuno-oncology drug combinations demonstrating improved outcomes, experts hope that the answer may be yes.

You may also be interested in...



Three key ingredients for Bayer's future growth

Three projects that will drive future growth were highlighted at Bayer's Perspective on Innovation 2014 Meeting, held in Leverkusen on 2 December 2014. The company singled out the protein free formulation of its blockbuster hemophilia A therapy Kogenate (BAY 81-8973), regorafenib eye drops for wet age-related macular degeneration, and the androgen receptor inhibitor ODM-201, which is partnered with Orion.

BioMarin's early data restores faith in real PARP inhibitors

Early Phase I/II trial data has restored hope that PARP inhibitors may be effective in treating cancer. The PARP inhibitor class took a hit from the failure of Sanofi's iniparib triple-negative breast cancer, but that molecule turned out not to be a PARP inhibitor at all. Now, according to data revealed at the European Cancer Congress (ECC) in Amsterdam on 29 September, around half of the heavily pretreated patients receiving Biomarin's BMN-673 demonstrated an objective response. BioMarin will begin a pivotal Phase III trial to determine the role of BMN-673 in the treatment of BRCA mutation-positive patients. The drug could become the first PARP inhibitor to gain approval for BRCA mutation-positive metastatic breast cancer.

Seattle's success with Adcetris could spark more antibody-drug conjugates investment

With an FDA panel unanimously recommending accelerated approval for Adcetris for relapsed/refractory Hodgkin's lymphoma and relapsed/refractory systemic anaplastic large cell lymphoma - and with treatment options for these indications limited - commercial success for the drug could attract further investment in antibody-drug conjugate (ADC) technologies.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132972

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel